Oncobiologics Q3 2025 Earnings Report

Oncobiologics EPS Results

• Actual EPS: -$0.44
• Consensus EPS: -$0.42
• Beat/Miss: Missed by -$0.02
• One Year Ago EPS: N/A

Oncobiologics Revenue Results

• Actual Revenue: $1.51 million
• Expected Revenue: $1.66 million
• Beat/Miss: Missed by -$157.00 thousand
• YoY Revenue Growth: N/A

Oncobiologics Announcement Details

• Quarter: Q3 2025
• Date: 8/14/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, August 14, 2025
• Conference Call Time: 12:00AM ET

Oncobiologics (NASDAQ:OTLK) is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary. This global footprint enables the company to conduct end-to-end process development and scale-up operations, optimizing both development timelines and production costs in major biopharmaceutical markets.

The company’s pipeline comprises multiple biosimilar candidates targeting established therapies in oncology and supportive care, with programs at various stages of preclinical and clinical development. Oncobiologics advances its portfolio through a disciplined clinical strategy and selective partnerships designed to streamline regulatory pathways. By focusing on broadening patient access to proven biologic medicines, the company seeks to address unmet needs in the United States, Europe and other global regions with its upcoming biosimilar products.